Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 400 Crossing Boulevard, 3rd Floor BRIDGEWATER NJ 08807 |
Tel: | N/A |
Website: | https://amneal.com |
IR: | See website |
Key People | ||
Chirag Patel President, Co-Chief Executive Officer, Co-Founder, Director | Chintu Patel Co-Chief Executive Officer, Co-Founder, Director | Anastasios G. Konidaris Chief Financial Officer, Executive Vice President |
Nikita Shah Chief Human Resource Officer, Executive Vice President | Andrew S. Boyer Executive Vice President, Chief Commercial Officer - Generics | Gustavo J. Pesquin Executive Vice President, Chief Commercial Officer - Speciality | Jason B. Daly Senior Vice President, Chief Legal Officer and Corporate Secretary |
Business Overview |
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company's Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment's portfolio includes central nervous system disorders (Parkinson's disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company's AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets. |
Financial Overview |
For the three months ended 31 March 2024, Amneal Pharmaceuticals Inc revenues increased 18% to $659.2M. Net loss increased from $6.9M to $91.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Legal Provisions/Litigation Expense increase from $436K (income) to $94.4M (expense), Selling, general and administrative increase of 10% to $112.6M (expense). |
Employees: | 7,700 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $4,703M as of Mar 31, 2024 |
Annual revenue (TTM): | $2,495M as of Mar 31, 2024 |
EBITDA (TTM): | $423.62M as of Mar 31, 2024 |
Net annual income (TTM): | -$168.69M as of Mar 31, 2024 |
Free cash flow (TTM): | $124.24M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | $2,648M as of Mar 31, 2024 |
Shares outstanding: | 460,768,373 as of Apr 30, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |